- |||||||||| Kisqali (ribociclib) / Novartis
Journal: The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer. (Pubmed Central) - Oct 28, 2024
P2
Comprehensive molecular biology procedures, including sequential single-cell RNA-sequencing of tumor biopsies, are performed during 6 months of treatment with extensive biobanking of blood samples, tumor biopsies and gut microbiome specimens. Our findings will hopefully contribute to an improved selection of patients who may benefit from this drug combination and give new insights into the intra-tumoral changes during this treatment.Trial registration number: NCT05163106 (ClinicalTrials.gov).
- |||||||||| letrozole / Generic mfg.
Journal: Aromatase inhibitors can improve the semen quality of aged roosters by up regulating genes related to steroid hormone synthesis. (Pubmed Central) - Oct 27, 2024
Furthermore, 8 genes including STAR, CYP17A1, NSDHL, SULT1E1, EHF, NRNPA1, PLIN2 and SDHA were identified as key genes for letrozole to regulate semen quality in aged roosters. These results indicate that letrozole can up-regulate the expression of genes related to steroid hormone synthesis, cell differentiation and proliferation, electron transfer activity, and enhance mitochondrial activity, increase testicular weight, and ultimately improve the semen quality of aged roosters.
- |||||||||| Evrenzo (roxadustat) / FibroGen
Preclinical, Journal: Roxadustat alleviates metabolic traits in letrozole-induced PCOS mice. (Pubmed Central) - Oct 26, 2024
Gene expression analyses with real-time quantitative polymerase chain reaction (RT-qPCR) and RNA sequencing revealed significant differences in gene expression in the tissues of PCOS mice compared to control mice, whereas the transcriptomic effects of roxadustat were mainly transient. However, immunohistochemistry revealed increased uncoupling protein 1 (UCP1) expression in WAT, which may indicate WAT browning related to HIF pathway activation.
- |||||||||| BIBR1532 / Boehringer Ingelheim, Bay11-7082 / Bayer
Preclinical, Journal, IO biomarker: The mechanism of NF-?B-TERT feedback regulation of granulosa cell apoptosis in PCOS rats. (Pubmed Central) - Oct 25, 2024
NF-?B and TERT inhibitors (BAY 11-7082 and BIBR1532) were then administered to LPS-induced KGN cells...LPS-treated KGN cells demonstrated increased expression of inflammatory and pro-apoptotic factors, later restored post-treatment with NF-?B and TERT inhibitors (P are all less than 0.05). In conclusion, TERT may induce granulosa cell apoptosis by participating in the regulation of the NF-?B signaling pathway, thereby mediating the chronic inflammatory response of PCOS through downstream inflammatory factors IL-6 and TNF-?.
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: REMEDIAL INTERVENTION OF FERTILITY AGENT AND GENE 35 ON INDUCED CYSTIC OVARY IN RATS. (Pubmed Central) - Oct 23, 2024
Therefore, current study is designed to estimate the role of Gene 35 and fertility supplements (composed from chasteberry, green tea extracts and L-arginine along with some elements),as alternative therapy for induced cystic ovary with letrozole in rats...From the current result, there is a noticeable improvement in number of ovarian cysts and hormones levels. Therefore, it is recommended that Gene 35 and fertility supplement can be used in the treatment of PCOS patients as supporting and treatment.
- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) (clinicaltrials.gov) - Oct 21, 2024
P2, N=137, Recruiting,
Therefore, it is recommended that Gene 35 and fertility supplement can be used in the treatment of PCOS patients as supporting and treatment. Trial completion date: Sep 2024 --> Aug 2029 | Trial primary completion date: Sep 2024 --> Feb 2026
- |||||||||| diacerein / Generic mfg., letrozole / Generic mfg.
Journal: Diacerein and myo-inositol alleviate letrozole-induced PCOS via modulation of HMGB1, SIRT1, and NF-kB: A comparative study. (Pubmed Central) - Oct 21, 2024
Diacerein possessed anti-inflammatory properties and showed significant efficacy in mitigating the endocrinal, metabolic, and ovarian structural alterations linked to PCOS. Its beneficial actions likely stem from reducing oxidative stress, dyslipidemia, and hyperglycemia, potentially through the modulation of HMGB1, SIRT1, and NF-kB pathways.
- |||||||||| metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
Review, Journal: Recent developments in drug treatment strategies for infertility in patients with polycystic ovary syndrome. (Pubmed Central) - Oct 21, 2024
The authors identify four primary areas of interest that have impacted clinical practice in the last few years. Specifically, they discuss the current role of metformin administration in women with PCOS and infertility, the choice for using clomiphene citrate or letrozole as first-line treatment for ovulation induction, the use of new gonadotropin formulations for in vitro fertilization (IVF) program, and the elective embryo transfer in IVF cycles as golden standard treatment for patients with PCOS at high-risk for ovarian hyperstimulation syndrome.
- |||||||||| letrozole / Generic mfg.
Clinical, Journal: Trends and Regional Differences for Fertility Preservation Procedures in Women With Breast Cancer. (Pubmed Central) - Oct 21, 2024
The utility of FP has steadily increased for young women with breast cancer over the last decade, although regional differences significantly influence FP practices. The findings of our study could have value for policy making in FP care for young women with breast cancer at the local, regional, or global level.
- |||||||||| Mekinist (trametinib) / Novartis, BeiGene
Review, Journal, Metastases: Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease? (Pubmed Central) - Oct 16, 2024
Recent advances in molecular profiling and the identification of new, promising targets, such as the mitogen-activated protein kinase (MAPK) pathway, offer hope for improving both the prognosis and health-related quality of life in affected patients. Given the high unmet clinical need to establish new therapeutic standards beyond cytotoxic chemotherapy, this review aims to summarize the most promising molecular targets and emerging targeted agents.
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal: Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring. (Pubmed Central) - Oct 16, 2024
Clinical validation supports DBS-based TDM as feasible, with conversion models developed for estimating plasma concentrations (the reference for TDM target values) of letrozole, abemaciclib, and its metabolites. Preliminary data for palbociclib and ribociclib are also presented.
- |||||||||| Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date: Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) - Oct 15, 2024
P4, N=137, Recruiting,
Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jul 2024 Trial completion date: Mar 2030 --> Feb 2028 | Trial primary completion date: Feb 2030 --> Jan 2028
- |||||||||| Kisqali (ribociclib) / Novartis
INVASIVE LOBULAR BREAST CANCER WITH METASTASES TO GATROINTESTINAL TRACT AND SKELETAL MUSCLES: A CASE REPORT () - Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_269;
She underwent left mastectomy and axillary clearance followed by adjuvant chemotherapy, radiotherapy and letrozole plus ovarian suppression...Hormone therapy was switched to exemestane...Her symptoms improved significantly with docetaxel chemotherapy, together with biochemical and radiological improvement...Further treatment with gemcitabine and carboplatin followed by fulvestrant and ribociclib combination did not manage to give good control...CONCLUSION This case highlights the unique presentation of a patient with metastatic ILC. Clinicians should have a high index of suspicion when dealing with unusual presentations in order for the appropriate treatment to be given.
- |||||||||| TRIPLE NEGATIVE INTERNAL MAMMARY LYMPH NODE RECURRENCE IN BRCA MUTANT ER POSITIVE EARLY BREAST CANCER () - Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_259;
She completed sequential 5-Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel adjuvant chemotherapy for 6 cycles, radiotherapy to the left chest wall and supraclavicular fossa 40 Grays in 15 fractions in November 2022, and on-going hormonal therapy, including Letrozole and Goserelin injection...Multidisciplinary approach with left IMLN resection, which revealed tumour biology transformation to triple negative, followed by 6 cycles of adjuvant paclitaxel carboplatin chemotherapy...CONCLUSION ILMN irradiation should be individualized after considering the prior therapy and potential cardio-pulmonary safety interaction with systemic therapy. Multidisciplinary approach of surgery followed by systemic therapy could be the treatment of choice for isolated IMLN recurrence.
- |||||||||| letrozole / Generic mfg., fulvestrant / Generic mfg.
Journal: Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation. (Pubmed Central) - Oct 10, 2024
P2
In an analysis of tumor specimens from 32 patients, tumors exhibiting residual cell proliferation after aromatase inhibitor-induced estrogen deprivation with letrozole showed increased mitochondrial content...Pharmacological inhibition of complex I suppressed the tumor-forming potential of persisters and synergized with the anti-estrogen fulvestrant to induce regression of patient-derived xenografts...Endocrine-tolerant persister cancer cells that survive endocrine therapy can cause recurrent disease. Persister cells exhibit increased energetic dependence upon mitochondria for survival and tumor re-growth potential.
- |||||||||| camizestrant (AZD9833) / AstraZeneca, saruparib (AZD5305) / AstraZeneca
Trial completion date: EvoPAR-Breast01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (clinicaltrials.gov) - Oct 10, 2024
P3, N=500, Recruiting,
Persister cells exhibit increased energetic dependence upon mitochondria for survival and tumor re-growth potential. Trial completion date: Jul 2030 --> Oct 2030
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Mangiferin ameliorates polycystic ovary syndrome in rats by modulating insulin resistance, gut microbiota, and ovarian cell apoptosis. (Pubmed Central) - Oct 8, 2024
In this study, we evaluated the effects of mangiferin on a letrozole (LET) combined with high-fat diet (HFD)-induced PCOS rat model through estrous cycle detection, serum/tissue biochemical analysis, and hematoxylin and eosin (HE) staining of ovarian tissue...Additionally, mangiferin significantly altered the gut microbiota community of PCOS rats, changing the abundance of firmicutes, bacteroidota, proteobacteria, and actinobacteria at the phylum level and the abundance of Blautia, Coprococcus, Roseburia, and Pseudomonas at the genus level. In conclusion, mangiferin is a promising and novel therapeutic agent for PCOS as it ameliorates insulin resistance, gut microbiota and ovarian cell apoptosis.
- |||||||||| letrozole / Generic mfg.
Journal: Non-Islet-Cell Tumor Hypoglycemia Secondary to Malignant Phyllodes Tumor of the Breast. (Pubmed Central) - Oct 7, 2024
The patient was treated with letrozole and adjuvant radiotherapy...Although glucocorticoid treatment has also been widely used for NICTH, few reports have demonstrated efficacy for NICTH secondary to phyllodes tumor. We report a rare case of malignant phyllodes tumor of the breast resulting in NICTH and demonstrated good response to glucocorticoids as a bridge to definitive surgery.
- |||||||||| letrozole / Generic mfg.
Journal: Disseminated peritoneal leiomyomatosis: A benign condition with diagnostic and therapeutic challenges. (Pubmed Central) - Oct 7, 2024
She was then placed on letrozole, which prevented further tumor growth and abated her symptoms...We report a case of DPL in a woman that was managed with surgical intervention and hormonal manipulation therapy following the failure of the initial surgical excision alone. We thus suggest a combination of surgical intervention and postoperative hormonal manipulation in its management, as such a multi-modality of therapy was employed in the index case without evidence of recurrence after a year post-surgery.
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Effects of letrozole on rat placental development. (Pubmed Central) - Oct 3, 2024
These changes are considered to be due to maternal blood circulation stagnation in the metrial gland, which is associated with dilated maternal sinusoids in the labyrinth zone. Thus, although letrozole induces an enlarged placenta due to congestive hyperemia of the labyrinth zone and transient increases in fetal weight, these placentas are thought to decline in function as the pregnancy progresses, leading to intrauterine growth restriction at the end of pregnancy.
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Rapid and local neuroestrogen synthesis supports long-term potentiation of hippocampal Schaffer collaterals-cornu ammonis 1 synapse in ovariectomized mice. (Pubmed Central) - Oct 1, 2024
To assess the impact of neuroestrogens synthesis on LTP, we applied the specific aromatase inhibitor, letrozole, before the induction of LTP with a theta burst stimulation protocol...Interestingly, exogenous E2 application, while blocking aromatase activity, was not sufficient to recover LTP in our model. Our results indicate the critical importance of rapid, activity-dependent local neuroestrogens synthesis, independent of circulating hormones for hippocampal synaptic plasticity in female rodents.
- |||||||||| Avastin (bevacizumab) / Roche
Journal: Case report: Report of a case of female adnexal malignant tumor of Wolffian origin. (Pubmed Central) - Oct 1, 2024
However, 1 year after surgery, she was diagnosed with stage IV fallopian tube cancer due to a recurrence, which presented with substantial ascites and invasion of multiple organs, including the bilateral ovaries, intestines, pelvic peritoneum, greater omentum, and appendix. After tumor cytoreduction, the patient responded well to treatment, which included a regimen of platinum-based drugs combined with docetaxel, aromatase inhibitors such as letrozole, antihormonal therapy, and targeted therapy with bevacizumab.
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion date: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Oct 1, 2024
P1, N=26, Active, not recruiting,
After tumor cytoreduction, the patient responded well to treatment, which included a regimen of platinum-based drugs combined with docetaxel, aromatase inhibitors such as letrozole, antihormonal therapy, and targeted therapy with bevacizumab. Trial completion date: Jan 2023 --> Dec 2024
- |||||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Sep 30, 2024
P1/2, N=255, Active, not recruiting,
Recruiting --> Completed | Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Mar 2023 --> Aug 2024 Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
- |||||||||| goserelin acetate / Generic mfg., letrozole / Generic mfg.
Journal, Heterogeneity: A weighted Bayesian integration method for predicting drug combination using heterogeneous data. (Pubmed Central) - Sep 29, 2024
This new method enhances the performance of drug combination predictions, enabling effective pre-screening for trials and, thereby, benefiting clinical treatments. Future research should focus on developing new methods for application in various scenarios and for integrating diverse data sources.
|
